Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

ChemoCentryx Shares Spike 300% on Phase 3 ANCA Vasculitis Trial Results

Shares of ChemoCentryx Inc. opened greater than 330% higher today after the firm reported positive topline data from its pivotal Phase 3 ADVOCATE trial of Avacopan in treatment of ANCA-associated vasculitis. After the U.S. markets closed yesterday, ChemoCentryx Inc. ...
Streetwise Reports | November 27, 2019 |

Ultragenyx Shares Increase 30% on Results from Phase 1/2 OTC Deficiency Study

Rare disease biopharmaceutical company Ultragenyx Pharmaceutical's shares traded 30% higher after the firm reported positive topline results from Cohorts 2 and 3 in its Phase 1/2 study of DTX301 gene therapy in Ornithine Transcarbamylase Deficiency. After U.S. markets...
Streetwise Reports | January 13, 2020 |

Mesoblast Shares Soar 120% After Reporting 83% Survival Rate in COVID-19 Patients with ARDS

Shares of Mesoblast more than doubled and set a new 52-week high price after the company reported that it achieved a 83% survival rate in New York ventilator-dependent COVID-19 patients with moderate to severe acute respiratory distress syndrome who were treated with its all...
Streetwise Reports | April 27, 2020 |

Biotech to Test Stem Cell Product in COVID-19-Caused Acute Respiratory Distress

A description of Mesoblast's multi-site clinical trial and possible implication for the therapeutic are provided in an H.C. Wainwright & Co. report. In an April 9 research note, H.C. Wainwright & Co. analyst Swayampakula Ramakanth reported that Mesoblast Lt...
Streetwise Reports | April 16, 2020 |

Buzz on the Bullboards: Interest rates are still high

Stocks on both sides of the border have wilted in this short trading week. Stocks have since suffered after the Bank of Canada said this week that it would hold its key interest rate at 5 per cent , a 22-year high. The rate pause is in line with economist expectation...
Jonathon Brown | September 7, 2023 |

'Stay Tuned for Data' from Regenerative Medicine Firm with 'Blockbuster Opportunity'

The compelling aspects of this life sciences story are presented in a Dawson James report. In a Jan. 28 research note, analyst Jason Kolbert reported that Dawson James Securities increased its target price on Mesoblast Ltd. (MESO:NASDAQ; MSB:ASX) to $15 pe...
Streetwise Reports | February 3, 2020 |

Biotech Identifies Antibody with 100% SARS-CoV-2 Inhibition

The goal of Sorrento Therapeutics to develop a Covid-19 antibody cocktail, including its progress, next steps and market opportunity, is reviewed in a Dawson James report. In a May 26 research note, Dawson James analyst Jason Kolbert reported that Sorrento Therape...
Streetwise Reports | May 28, 2020 |

Malevolent Microbes

There is a local casino just "up the road" from where we reside that we visit (once in a blue moon), small sums of pocketed cash in hand, to play a few favored slot machines to see if we can defy the house odds and come home winners. Called The Great Blue Heron Casino, we...
Streetwise Reports | January 28, 2020 |

Pure. Enhanced. Proven. The Cannabis Co. That’s Ready to Grow.

(Click image above to play video) Investors know the cannabis market is back and are looking for real value and opportunity in the rebounding space. And while many companies are called…few are chosen. 1933 Industries (TGIF) ( CSE:TGIF , OTCQX: TGIFF , Foru...
Dave Jackson | March 23, 2021 |